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incidence and epidemiology
Diffuse large B-cell lymphoma (DLBCL) constitutes 30%–58% of
non-Hodgkin’s lymphoma series. The crude incidence in Europe is
3.8/100 000/year [1]. The incidence increases with age and varies
considerably across Europe. A family history of lymphoma, auto-
immune disease, human immunodeficiency virus (HIV) infection,
hepatitis C virus (HCV) seropositivity, a high body mass as a young
adult and some occupational exposures have been identified as risk
factors of DLBCL [2]. In recent years, there have been important
survival improvements for DLBCL in all European regions [3].
diagnosis and pathology/molecular
biology
The diagnosis of DLBCL should be carried out in a reference
haematopathology laboratory with expertise in morphological
interpretation and the facilities to carry out the full range of
phenotypic and molecular investigations [V, A].
A surgical excision biopsy remains the optimal method of diag-
nosis [V, A]. This allows assessment of nodal architecture and pro-
vides adequate material for phenotypic and molecular studies.
Ideally, the biopsy should be sent unfixed to the laboratory to allow
flow cytometric studies to be carried out and high-quality DNA and
RNA to be extracted. Needle-core and endoscopic biopsies should
be reserved for patients for whom a surgical approach is impractical
or would entail excessive risk [IV, B]. A fine-needle aspirate should
not be used as the sole basis for a diagnosis of DLBCL [V, E].
A morphological diagnosis of DLBCL should be confirmed in
all cases by immunophenotypic investigations, either
immunohistochemistry (IHC) or flow cytometry or a combin-
ation of both techniques [V, A]. Panels used must be designed
to confirm B-cell lineage, and must be comprehensive enough to
highlight possible variant forms such as immunoblastic lymph-
oma [4], primary mediastinal B cell lymphoma (PMBCL), T-cell/
histiocyte rich large B-cell lymphoma, primary cutaneous
DLBCL leg-type or EBV-positive DLBCL of the elderly. They
must also distinguish alternative diagnoses that may be difficult
to make on the basis of morphology alone, and which have im-
portant clinical consequences as plasmablastic lymphoma or
soft tissue involvement by myeloma, Burkitt lymphoma, unclas-
sifiable B-cell lymphoma with features intermediate between
diffuse large cell lymphoma and Burkitt lymphoma, blastic
mantle cell lymphoma and some cases of Hodgkin’s lymphoma.
A suggested immunohistochemical panel would include CD20,
CD79a, BCL6, CD10, MYC, BCL2, Ki67, IRF4, CyclinD1, CD5
and CD23. EBER-1 staining may be used to identify the
Epstein–Barr virus-positive DLBCL subtype of the elderly popu-
lation. The histological report should give the diagnosis accord-
ing to the current World Health Organization classification [5].
Where the level of confidence in the diagnosis is reduced, for
example, because only a small biopsy specimen is available or
where the putatively neoplastic population has a normal pheno-
type by IHC, demonstration of B-cell monoclonality by a poly-
merase chain reaction-based method should be considered
[IV, C] [6].
The cell of origin phenotype determined by gene expression
profiling is also a major prognostic factor in DLBCL [7–9].
Tumours with a germinal centre phenotype have a significantly
better clinical outcome that those with an activated B-cell pheno-
type. The nature of type 3 or unclassified subgroups requires
further clarification. Newer methods, based on evaluation of a
limited set of genes, have been validated in comparison with
standard gene expression, and are now used in the setting of clin-
ical trials [9, 10]. Cell of origin can also be determined by IHC
but published data on the prognostic effect of immunohistochem-
ical techniques are contradictory, and it is not recommended to
routinely base clinical decisions on these results [11, 12]. General
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issues of reproducibility may also limit the value of IHC as a prog-
nostic biomarker [13].
The presence of an MYC rearrangement in combination
with BCL2 rearrangement, and possibly other genetic abnor-
malities, has been described as a special entity (‘double-hit’ or
‘triple-hit’ lymphoma). However, the prognostic significance
of these rearrangements remains controversial and optimal
clinical management is not established [14–16]. This assess-
ment is recommended, wherever technically possible, in newly
diagnosed and relapsed patients being treated with curative
intent, using interphase fluorescence in situ hybridisation [IV,
B]. The immunohistochemical expression of MYC and/or
BCL2 or both (double expressors) is only partly correlated
with genetic abnormalities, but the concurrent expression of
MYC and BCL2 is usually associated with a poor outcome
[17–19].
staging and risk assessment
Physical examination, performance status (PS) and assessment
of B symptoms are necessary [V, A]. A complete blood count,
routine blood chemistry including lactate dehydrogenase
(LDH) and uric acid, as well as screening tests for HIV, hepa-
titis B virus (HBV) (HBs antigen, anti-HBs and anti-HBc anti-
bodies) and HCV are required [V, A]. Protein electrophoresis
is recommended [IV, B].
Based on recent consensus recommendations for staging and
restaging of lymphoma developed by the clinical and imaging
working groups of the international conference of malignant
lymphomas (Lugano classification), fluorodeoxyglucose positron
emission tomography (FDG-PET)/computed tomography (CT)
scan is now recommended as the gold standard for staging
DLBCL patients [V, A] [20, 21]. PET/CT is more accurate than
contrast-enhanced CT (CeCT), with increased sensitivity for
nodal and extranodal sites; in practice, CeCT is often carried out
before PET/CT. Should this not be the case, a full diagnostic
high-dose CeCT should be carried out when necessary, in com-
bination with PET/CT and after the PET scan [V, B]. Indeed,
CeCT may be necessary for a better delineation of lymphadenop-
athy from the bowel; the detection of compression/thrombosis of
central/mediastinal vessels, radiation planning or a more accurate
measurement of nodal sites in the context of a trial. The findings
of CeCT when carried out at baseline determine whether the low-
dose non-enhanced CT part of the PET/CT scan will be sufficient
for restaging.
Focal bone marrow FDG uptake with or without increased
diffuse uptake is more sensitive than bone marrow biopsy (BMB)
for infiltration in DLBCL and is highly specific [22]. Low-volume
involvement (<10%–20%) and discordant lymphoma may be
missed by PET/CT imaging but these positive BMB/negative
PET/CT findings are <10% [23]. Thus, biopsy is no longer
required when a PET/CT scan demonstrates bone or marrow in-
volvement indicating advanced-stage disease but is appropriate in
case of negative PET, when its results would change prognosis
and treatment, especially when a shortened number of immuno-
chemotherapy cycles is proposed [V, C].
For suspected central nervous system (CNS) lymphoma, mag-
netic resonance imaging is the modality of choice [III, A].
A diagnostic lumbar puncture should be considered in high-
risk patients as described above [V, A]. Flow cytometry, when
available, enhances the detection of lymphoma cells in the cere-
brospinal fluid [24].
Cardiac function (left ventricular ejection fraction) should be
assessed before treatment [V, A]. The risks of infertility and pos-
sibilities of fertility preservation should be discussed, depending
on the type of treatment being proposed.
The staging is established according to the Ann Arbor classifi-
cation system [I, A] (Table 1). A new staging system that has not
been prospectively validated has been recently proposed [20].
For prognostic purposes, the International Prognostic Index
(IPI) and age-adjusted IPI (aaIPI) should be calculated [I, A]
[25] (Table 2). Other factors that may affect prognosis and treat-
ment strategies, including the maximum bulk of the disease,
should be assessed [30].
Table 1. Ann Arbor staging classification
Stage
I Involvement of a single lymphatic region (I) or localized
involvement of single extralymphatic organ or site (IE)
II Involvement of two or more lymphatic regions on the same side
of the diaphragm (II) or localized involvement of a single
extralymphatic organ or site and of one or more lymphatic
regions on the same side of the diaphragm (IIE)
III Involvement of lymphatic regions on both sides of the diaphragm
IV Diffuse or disseminated involvement of one or more
extralymphatic organs with or without lymphatic involvement
Table 2. International prognostic index (IPI)
International prognostic index (IPI) Estimated 3-year
overall survival
[26–29] (95% CI)
Risk factors Age >60 years
Serum LDH > normal
Stage III–IV
Performance status 2–4
Extranodal sites >1
Risk categories Low 0–1 91 (89–94)
Low intermediate 2 81 (73–86)
High intermediate 3 65 (58–73)
High 4–5 59 (49–69)
Age-adjusted international prognostic index
(aaIPI) in patients ≤60 years
Risk factors Serum LDH > normal
Stage III–IV
Performance status 2–4
Risk categories Low 0 98 (96–100)
Low intermediate 1 92 (87–95)
High intermediate 2 }75 (66–82)High 3
LDH, lactate dehydrogenase; CI, confidence interval.
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treatment
Treatment strategies should be stratified according to age,
IPI and feasibility of dose-intensified approaches (Table 3).
Whenever available, the inclusion in a clinical trial is
recommended.
In cases with high tumour load, precautions such as the ad-
ministration of prednisone (p.o.) several days as ‘prephase’
treatment are advised to avoid tumour lysis syndrome [I, A].
Dose reductions due to haematological toxicity should be
avoided [I, A]. Febrile neutropaenia justifies prophylactic use of
haematopoietic growth factors in patients treated with curative
intent and in patients older than 60 years of age [I, A].
young low-risk patients (aa-IPI = 0) without
bulky disease
Six cycles of combination chemotherapy with cyclophospha-
mide, doxorubicin, vincristine and prednisone (CHOP) treat-
ment combined with six doses of rituximab given every 21 days
is the current standard [I, A] [31]. Consolidation by radiother-
apy to initial non-bulky sites has no proven benefit in patients
treated with rituximab or not [I, A] [32, 33].
Table 3. Recommended treatment strategies in diffuse large B-cell lymphoma
Patients ≤60 years
IPI low risk (aaIPI = 0) and no bulk IPI low risk (aaIPI = 0) with bulk or IPI
low-intermediate risk (aaIPI = 1)
IPI intermediate-high risk or IPI high risk
(aaIPI = 2, 3)
R-CHOP21 × 6 R-ACVBP and sequential consolidation
or
R-CHOP21 × 6 + IF-RT on bulk
R-CHOP21 × 6–8
or
R-CHOP14 × 6 with 8 R
Consider more intensive regimens in
selected patients:
R-CHOEP14 × 6
or
R-CHOP or R-ACVBP plus HDCTwith
ASCT
Consider CNS prophylaxis in patients at risk for CNS progression
Elderly >60 years
Fit, 60–80 years >80 years without cardiac dysfunction Unfit or frail or >60 years with cardiac
dysfunction
R-CHOP21 × 6–8
(R-CHOP21 × 6 for IPI low risk)
or
R-CHOP14 × 6 with 8 R
Attenuated regimens:
R-miniCHOP21 × 6
Doxorubicin substitution with
gemcitabine, etoposide or liposomal
doxorubicin or others:
R-C(X)OP21 × 6
or
palliative care
Consider CNS prophylaxis in patients at risk
First relapse/progress
Eligible for transplant Not eligible for transplant
Platinum-based chemotherapy regimens (i.e. R-DHAP, R-ICE, R-
GDP) as salvage treatment
For chemosensitive patients: R-HDCT with ASCT as
remission consolidation
Consider allogeneic transplantation in patients relapsed
after R-HDCT with ASCT or in patients with
poor-risk factors at relapse
Platinum- and/or gemcitabine-based
regimens
Clinical trials with novel drugs
>2 relapse/progress
Eligible for transplant Not eligible for transplant
Allogeneic transplantation
Clinical trials with novel drugs
Clinical trials with novel drugs
Palliative care
IPI, International Prognostic Index; aaIPI, age-adjusted IPI; R, rituximab; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; ACVBP,
doxorubicin, vindesine, cyclophosphamide, bleomycin and prednisolone; IF-RT, involved-field radiotherapy; HDCT, high-dose chemotherapy; ASCT,
autologous stem-cell transplantation; DHAP, cisplatin, cytarabine, dexamethasone; ICE, ifosfamide, carboplatin, etoposide; GDP, cisplatin, gemcitabine,
dexamethasone; CNS, central nervous system; CHOEP, cyclophosphamide, doxorubicin, vincristine, etoposide, prednisolone; R-C(X)OP, R-CHOP with
substitution of doxorubicin.
v | Tilly et al. Volume 26 | Supplement 5 | September 2015
clinical practice guidelines Annals of Oncology
 by guest on O
ctober 30, 2016
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
young low-intermediate-risk patients (aa-IPI = 1)
or IPI low risk (aa-IPI = 0) with bulky disease
Rituximab (R)-CHOP 21 × 6 with radiotherapy to the sites of
previous bulky disease was shown to be effective in this group of
patients, based on the results of the MINT study [II, B] [31].
Alternatively, an intensification of chemotherapy with R-ACVBP
(rituximab, doxorubicin, vindesine, cyclophosphamide, bleo-
mycin and prednisolone), given every 2 weeks followed by
sequential consolidation, has been shown to improve survival
compared with eight cycles of R-CHOP in this category, but
radiotherapy was omitted in both arms of this trial [I, A] [26].
In this group of patients, either R-CHOP21 × 6 with radiother-
apy to the sites of previous bulky disease or the intensified
regimen R-ACVBP is recommended [II, B].
young high- and high-intermediate-risk patients
(aa-IPI≥ 2)
There is no current standard in this subgroup, and in this group
especially, enrolment in clinical trials should be a priority. Six to
eight cycles of chemotherapy with CHOP combined with eight
doses of rituximab given every 21 days are most frequently
applied [III, B]. Dose dense treatment with R-CHOP given every
14 days has not demonstrated a survival advantage over standard
R-CHOP given every 21 days [I, C] [34]. In this trial, R-CHOP 14
failed to show a better outcome in any DLBCL subset, including
young poor-risk patients, although the trial was not powered to
compare multiple clinical subgroups. Intensive treatment with
R-ACVBP or R-CHOEP (rituximab, cyclophosphamide, doxo-
rubicin, vincristine, etoposide and prednisolone) is frequently
used but these regimens have not been directly compared with
R-CHOP in this category [II, B] [27, 35].
Four randomised trials comparing rituximab chemotherapy
(R-chemotherapy) followed by high-dose chemotherapy
(HDC) and autologous stem-cell transplantation (ASCT)
versus R-chemotherapy alone have been presented. Two trials
showed a progression-free survival (PFS) benefit for HDC
with ASCT but no impact, at present, on overall survival (OS)
[36, 37], while two trials failed to demonstrate an improve-
ment for the HDC arm [35, 38]. Therefore, HDC with ASCT
in first line remains experimental or may be proposed for
selected high-risk patients [II, C]. The role of consolidation by
radiotherapy to initial sites of bulky disease is unknown. The
role of interim PET to select patients who could benefit from
consolidative ASCT [39] or from radiotherapy [40] is under
evaluation [I, C].
patients aged 60–80 years
Six to eight cycles of combination chemotherapy with CHOP
plus eight doses of rituximab given every 21 days is the current
standard [I, A] [41]. R-CHOP given every 14 days did not dem-
onstrate a survival advantage over R-CHOP 21 [I, C] [34, 42]. If
R-CHOP is given every 14 days, six cycles of CHOP with eight
cycles of rituximab are sufficient [I, A] [43]. In patients with
localised disease (IPI = 0), no benefit of consolidation by radio-
therapy was shown in patients treated before the introduction of
rituximab [I, A] [44], but a recent study indicated that irradi-
ation could improve the outcome of elderly patients with bulky
disease [II, C] [45]. In a phase II study, extended rituximab
exposure has been shown to improve outcome of elderly poor-
prognosis patients without increasing toxicity [III, C] [46]. A
comprehensive geriatric assessment in order to ascertain co-
morbidities and functional decline is recommended to guide the
choice of treatment in these patients [III, A] [47, 48]. R-CHOP
treatment can usually be used up to 80 years of age in fit patients
[I, A] but modulation of treatment according to geriatric assess-
ment is recommended [III, C] [49].
patients aged >80 years
The combination of rituximab with attenuated chemotherapy,
such as R-miniCHOP, can induce complete remission and long
survival in fit patients older than 80 years [III, B] [50].
Substitution of doxorubicin by gemcitabine, etoposide or liposo-
mal doxorubicin, or even its omission, can be considered from
the beginning or after a few cycles in patients with cardiac dys-
function or who are frail or unfit [III, C] [51].
central nervous system (CNS) prophylaxis
Patients with high-intermediate and high-risk IPI, especially
those with more than one extranodal site or elevated LDH, are
at higher risk of CNS relapse [52]. Testicular, renal and adrenal
involvements have been validated as additional risk factors [53].
CNS prophylaxis should be recommended in these populations
[II, A]. MYC gene rearrangement is associated with a high risk of
CNS relapse [43]. Although widely used, intrathecal injections of
methotrexate may not be an optimal method. Intravenous high-
dose methotrexate has been shown to be associated with efficient
disease control [IV, C] [54–56]. Prospective trials are ongoing to
evaluate this alternative approach.
some DLBCLs require special consideration
• Extranodal DLBCLs and PMBCLs are considered in other
guidelines.
• Patients with HIV infection should usually receive the same
treatment as HIV-negative patients in association with anti-
viral therapy [II, A] [57].
• Patients previously exposed to HBV (HBs antigen-negative,
anti-HBc-positive) are at risk of reactivation during treatment
with R-CHOP. Antiviral prophylaxis or periodic HBV DNA
monitoring and antiviral treatment in the case of reactivation
are recommended [III, A] [58].
response evaluation
post-treatment evaluation
FDG-PET/CT is now the recommended standard for post-treat-
ment assessment in DLBCL [I, A] [59]. The recent Lugano classifi-
cation based on the visual Deauville criteria (5-point scale, Table 4)
Table 4. PET 5-point scale (Deauville criteria)
1 No uptake
2 Uptake ≤mediastinum
3 Uptake >mediastinum but ≤liver
4 Moderately increased uptake compared with liver
5 Markedly increased uptake to liver and/or new lesions
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has proposed different response categories, termed ‘metabolic
response categories’ [20, 21]:
• Complete metabolic response (CMR) is defined when no
residual uptake exists or if the residual uptake is lower to or
equal to the liver activity (Deauville score 1–3), with or
without evidence of residual mass on the CT part of the exam-
ination, and without FDG-avid lesions in the bone marrow.
Since most patients with score 3 (uptake greater than medias-
tinal activity) have a good prognosis with standard treatment,
score 3 has been included in the CMR category but a careful
evaluation of these patients is recommended.
• Deauville scores 4 and 5 indicate residual disease in most
cases. Three categories of response are defined by comparing
the residual uptake with the tumour uptake in baseline scan:
partial metabolic response when the uptake has decreased, no
metabolic response when it has not changed or progressive
metabolic disease (PMD) when it has increased. A new site of
FDG uptake consistent with lymphoma is graded score 5 and
indicates a PMD but should be biopsied or followed by inter-
val scans in case of aetiological uncertainties. In the presence
of residual metabolically active tissue, where salvage treatment
is being considered, a biopsy is recommended [III, A].
interim evaluation
Mid-treatment imaging after three to four cycles may be used to
rule out progression in clinical practice [V, B]. It is usually carried
out with CT but PET/CT can also be used when available [20].
Changing treatment solely on the basis of interim PET/CT is dis-
couraged [II, E], unless there is clear evidence of progression.
Early PET evaluation carried out after one to two cycles of
treatment has been shown to be predictive of outcome, but
should be reserved for clinical trials at the present time [II, D].
follow-up
Patients with DLBCL who are event-free at 2 years have an iden-
tical OS to that of the general population, emphasising the need
to only specifically monitor the disease in this early period [60].
Careful history and physical examination every 3 months for
1 year, every 6 months for 2 more years and then once a year
with attention to development of secondary tumours or other
long-term side-effects of chemotherapy is recommended [V, D].
Blood count should be carried out at 3, 6, 12 and 24 months,
then only as needed for evaluation of suspicious symptoms or
clinical findings in those patients suitable for further therapy [V, C].
Minimal radiological examinations at 6, 12 and 24 months
after end of treatment by CT scan are common practice, but
there is no definitive evidence that routine imaging in patients in
complete remission provides any outcome advantage, and it may
increase the incidence of secondary malignancies [V, D] [61, 62].
Routine surveillance with PET scan is not recommended [V, E].
High-risk patients with curative options may potentially mandate
more frequent evaluation.
relapsed and refractory DLBCL
incidence. Overall, more than 30% of DLBCL will ultimately
relapse. The incidence in the European Union is therefore estimated
to be around 1/100 000/year. In addition to initial prognostic
factors, the nature of previous treatments and time from initial
treatment are of utmost importance [63].
diagnosis. In patients who are suspected of having relapsed on
the basis of imaging studies, the diagnosis should be confirmed
by biopsy before proceeding to second-line therapy. In these
circumstances, a needle-core biopsy is acceptable as primary
investigation.
staging and risk assessment. Patients still amenable to curative
therapy should have the same examinations as at first diagnosis.
treatment. The following recommendations apply to patients
who received adequate rituximab and anthracycline-containing
first-line therapy.
In patients aged <65–70 years with good PS and no major
organ dysfunction, salvage regimens with rituximab and chemo-
therapy followed, in responsive patients, by HDC and ASCT,
are recommended [II, A] [63–65] Salvage regimens such as
R-DHAP (rituximab, cisplatin, cytarabine, dexamethasone) or
R-ICE (rituximab, ifosfamide, carboplatin, etoposide) appear to
have similar outcomes [I, A] [63]. However, R-GDP (rituximab,
cisplatin, gemcitabine, dexamethasone) has been shown to have
similar efficacy but less toxicity than R-DHAP [I, A] [66]. One
study suggested a possible advantage of R-DHAP in the germi-
nal centre B-cell subtype, but this needs confirmation [IV, C]
[67]. BEAM (carmustine, etoposide, cytarabine and melphalan)
is the most commonly used high-dose regimen [III, B].
Additional involved-field radiation or iceberg radiation may
be used, especially in the few cases with limited stage disease,
but this has never been evaluated in controlled trials [IV, C].
Maintenance with rituximab is not recommended [I, E] [68].
Allogeneic transplantation with a sibling or matched unrelated
donor may be considered in patients with refractory disease,
early relapse or relapse after ASCT [III, B] [69].
Patients not suitable for high-dose therapy may be treated with
the same or other salvage regimens as R-GEMOX (rituximab,
gemcitabine, oxaliplatin) [III, B] [70]. Pixantrone, a new anthra-
cycline-like drug with reduced cardiotoxicity, demonstrated some
efficacy in heavily treated patients [II, C] [71]. However, these
patients should be preferably enrolled in clinical trials testing the
activity of other novel drugs.
response evaluation. Response criteria are identical to those of
first-line treatment evaluation. An evaluation should be carried out
after three to four cycles of the salvage regimen (before high-dose
treatment) and after the end of all therapy. Results of PET before
high-dose treatment are correlated to clinical outcome [72].
follow-up. Follow-up of patients in second response is the same
as for first response.
personalised medicine
Progress in the knowledge of pathological and molecular hetero-
geneity of DLBCL has led to the study of new agents that have
distinct activity in molecular subtypes, or have specific efficacy
on molecular targets involved in disease pathogenesis. At the
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Table 5. Summary of recommendations
Diagnosis and pathology/molecular biology
• Diagnosis should be carried out in a reference haematopathology laboratory with expertise in morphological interpretation and the facilities to carry out
the full range of phenotypic and molecular investigations [V, A].
• Surgical biopsy is the optimal method of diagnosis. [V, A].
• Needle-core and endoscopic biopsies should be reserved for patients for whom a surgical approach is impractical or would entail excessive risk [IV, B].
• A fine-needle aspirate should not be used as the sole basis for a diagnosis of DLBCL [V, E].
• A morphological diagnosis of DLBCL should be confirmed in all cases by immunophenotypic investigations [V, A].
• If there is doubt in the diagnosis, demonstration of B-cell monoclonality by a PCR-based method should be considered [IV, C].
• Assessment of MYC and BCL2 rearrangement is recommended (whenever technically possible) in newly diagnosed and relapsed patients treated with
curative intent, using interphase FISH [IV, B].
Staging and risk assessment
• Physical exam, performance status and assessment of B symptoms are necessary [V, A].
• A complete blood count, routine blood chemistry including LDH and uric acid, as well as screening tests for HIV, HBV and HCV are required [V, A].
• Protein electrophoresis is recommended [IV, B].
• FDG-PET/CT scan is recommended as the gold standard for staging DLBCL patients [V, A].
• If CeCT is not carried out before PET/CT, a full diagnostic high-dose CeCT should be carried out when necessary, in combination with PET/CT [V, B].
Biopsy may be avoided when PET/CT scans demonstrate bone or marrow involvement indicating advanced-stage disease but is appropriate in the case of
negative PET, when its results would change prognosis and treatment, especially when a shortened number of immunochemotherapy cycles is proposed
[V, C].
• For suspected CNS lymphoma, MRI is the modality of choice [III, A].
• A diagnostic lumbar puncture should be considered in high-risk patients [V, A].
• Cardiac function (LVEF) should be assessed before treatment [V, A].
• The staging is established according to the Ann Arbor classification system [I, A].
• For prognostic purposes, the IPI and aa-IPI should be calculated [I, A].
Treatment
• Treatment strategies should be stratified according to age, IPI and feasibility of dose-intensified approaches.
• Whenever available, inclusion in a clinical trial is recommended.
• In cases with high tumour load, precautions are advised to avoid tumour lysis syndrome [I, A].
• Dose reductions due to haematological toxicity should be avoided whenever possible [I, A].
• The risk of febrile neutropenia justifies prophylactic use of haematopoietic growth factors in patients treatment with curative intent and in
patients >60 years of age [I, A].
• For young, low-risk patients (aa-IPI = 0) without bulky disease:
○ six cycles of combination chemotherapy with CHOP treatment combined with six doses of rituximab given every 21 days is the current standard [I, A];
○ consolidation by radiotherapy to initial non-bulky sites has no proven benefit in patients treated with rituximab or not [I, A].
• For young low-intermediate-risk patients (aa-IPI = 1) or IPI low risk (aa-IPI = 0) with bulky disease:
○ either R-CHOP21 × 6 with radiotherapy to the sites of previous bulky disease or the intensified regimen R-ACVBP is recommended [II, B].
• For young high- and high-intermediate-risk patients (aa-IPI≥ 2):
○ enrolment in clinical trials should be a priority;
○ six to eight cycles of chemotherapy with CHOP combined with eight doses of rituximab given every 21 days are most frequently applied [III, B];
○ dose dense treatment with R-CHOP given every 14 days has not demonstrated a survival advantage over standard R-CHOP given every 21 days [I, C];
○ intensive treatment with R-ACVBP or R-CHOEP is frequently used but these regimens have not been directly compared with R-CHOP in this category
[II, B];
○ HDC with ASCT in first line remains experimental or may be proposed for selected high-risk patients [II, C];
○ the role of interim PET to select patients who could benefit from consolidative ASCT or from radiotherapy is under evaluation [I, C].
• For patients aged 60–80 years:
○ six to eight cycles of combination chemotherapy with CHOP plus eight doses of rituximab given every 21 days is the current standard [I, A];
○ if R-CHOP is given every 14 days, six cycles of CHOP with eight cycles of rituximab are sufficient [I, A];
○ a comprehensive geriatric assessment in order to ascertain comorbidities and functional decline is recommended to guide the choice of treatment in
elderly poor-prognosis patients [III, A];
○ R-CHOP treatment can usually be used up to 80 years of age in fit patients [I, A], but modulation of treatment according to geriatric assessment is
recommended [III, C].
• For patients aged >80 years:
○ the combination of rituximab with attenuated chemotherapy, such as R-miniCHOP, can induce complete remission and long survival in fit patients
older than 80 years [III, B];
○ substitution of doxorubicin by gemcitabine, etoposide or liposomal doxorubicin, or even its omission, can be considered from the beginning or after a
few cycles in patients with cardiac dysfunction or who are frail or unfit [III, C].
Continued
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Table 5. Continued
• CNS prophylaxis:
○ should be recommended for patients with high-intermediate-risk and high-risk IPI, especially those with more than one extranodal site or elevated
LDH or for patients with testicular, renal or adrenal involvement [II, A];
○ intravenous high-dose methotrexate has been shown to be associated with efficient disease control [IV, C].
• Patients with human immunodeficiency virus (HIV) infection should usually receive the same treatment as HIV-negative patients in association with
antiviral therapy [II, A].
• Antiviral prophylaxis or periodic HBV DNAmonitoring and antiviral treatment are recommended for patients previously exposed to HBV who
experience reactivation of the virus during treatment [III, A].
Response evaluation
• FDG-PET/CT is the recommended standard for post-treatment assessment in DLBCL [I, A].
• In the presence of residual metabolically active tissue, where salvage treatment is being considered, a biopsy is recommended [III, A].
• Interim evaluation:
○mid-treatment imaging after three to four cycles may be used to rule out progression in clinical practice [V, B];
○ changing treatment solely on the basis of interim PET/CT is discouraged [II, E], unless there is clear evidence of progression;
○ early PET evaluation carried out after one to two cycles of treatment has been shown to be predictive of outcome, but should be reserved for clinical
trials at the present time [II, D].
Follow-up
• Careful history and physical examination every 3 months for 1 year, every 6 months for 2 further years and then once a year with attention to
development of secondary tumours or other long-term side-effects of chemotherapy is recommended [V, D].
• Blood count should be carried out at 3, 6, 12 and 24 months, then only as needed for evaluation of suspicious symptoms or clinical findings in those
patients suitable for further therapy [V, C].
• Minimal radiological examinations at 6, 12 and 24 months after end of treatment, by CT scan, is common practice, but there is no definitive evidence
that routine imaging in patients in complete remission provides any outcome advantage and it may increase the incidence of secondary malignancies
[V, D]. Routine surveillance with PET scan is not recommended [V, E].
DLBCL, diffuse large B-cell lymphoma; PCR, polymerase chain reaction; FISH, fluorescence in situ hybridisation; LDH, lactate dehydrogenase; HIV,
human immunodeficiency virus; HBV, hepatitis B virus; HCV, hepatitis C virus; FDG, fluorodeoxyglucose; PET, positron emission tomography; CT,
computed tomography; CeCT, contrast-enhanced CT; CNS, central nervous system; MRI, magnetic resonance imaging; LVEF, left ventricular ejection
fraction; IPI, International Prognostic Index; aa-IPI, age-adjusted IPI; CHOP, cyclophosphamide, doxorubicin, vincristine and prednisone; R, rituximab; R-
AVCBP, rituximab, doxorubicin, vindesine, cyclophosphamide, bleomycin and prednisolone; R-CHOEP, rituximab, cyclophosphamide, doxorubicin,
vincristine, etoposide and prednisolone; HDC, high-dose chemotherapy; ASCT, autologous stem-cell transplantation.
Table 6. Levels of evidence and grades of recommendation (adapted from the Infectious Diseases Society of America-United States Public Health
Service Grading Systema)
Levels of evidence
I Evidence from at least one large randomised, controlled trial of good methodological quality (low potential for bias) or meta-
analyses of well-conducted randomised trials without heterogeneity
II Small randomised trials or large randomised trials with a suspicion of bias (lower methodological quality) or meta-analyses of
such trials or of trials with demonstrated heterogeneity
III Prospective cohort studies
IV Retrospective cohort studies or case–control studies
V Studies without control group, case reports, experts opinions
Grades of recommendation
A Strong evidence for efficacy with a substantial clinical benefit, strongly recommended
B Strong or moderate evidence for efficacy but with a limited clinical benefit, generally recommended
C Insufficient evidence for efficacy or benefit does not outweigh the risk or the disadvantages (adverse events, costs,… ),
optional
D Moderate evidence against efficacy or for adverse outcome, generally not recommended
E Strong evidence against efficacy or for adverse outcome, never recommended
aBy permission of the Infectious Diseases Society of America [86].
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present time, pending results of large comparative studies, none
of these agents is appropriate for routine therapy in practice.
The activated B-cell (ABC) subtype has been shown to have a
worse prognosis when compared with germinal centre B-cell
(GCB) in patients treated by R-CHOP [8]. A subgroup analysis
suggested that R-ACVBP could have a survival benefit over R-
CHOP in the non-GCB population [III, C] [73]. The ABC
subtype is characterised by a constitutive activation of the
NF-κB pathway, which could be targeted by different agents
as bortezomib and lenalidomide. Bortezomib combined with
dose-adjusted-EPOCH (etoposide, vincristine, doxorubicin,
cyclophosphamide and prednisone) (DA-EPOCH) has shown
selective activity in a small study of relapsed/refractory ABC-
DLBCL [74]. A UK/Swiss phase III trial (REMoDL-B) compar-
ing R-CHOP with R-CHOP-bortezomib in gene expression
prolife defined cell of origin subgroups of DLBCL is nearly com-
pleted. Lenalidomide, as a single agent, demonstrated selective
efficacy in the non-GCB subtype [75, 76]. In two phase II
studies, the combination of lenalidomide and R-CHOP showed
acceptable toxicity [77, 78]. In one of these studies, the PFS and
OS of the patients treated with the combination were identical
in non-GCB and GCB subtypes [78], leading to the initiation of
a randomised study in the ABC subtype.
Ibrutinib, a novel oral Bruton’s tyrosine kinase inhibitor, has
shown selective activity in ABC-DLBCL. The combination of
ibrutinib with R-CHOP has demonstrated promising responses,
leading to the initiation of a phase III trial in the non-GCB
population [79].
DLBCL with MYC rearrangement and/or MYC overexpres-
sion is usually considered a subgroup with aggressive behaviour.
However, many uncertainties remain about the extent of this
subgroup concerning translocation partners, additional defects
(double or triple hit), combination of genetic abnormalities and
MYC protein overexpression and dual overexpression with
MYC and BCL2 [80]. Although R-CHOP gives poor outcomes
for double-hit lymphomas, only preliminary results have sug-
gested better results with more intensive regimens, and clinical
trials are required in this subtype [81, 82].
Whole-genome next-generation sequencing studies have
identified frequent and recurrent mutations which may play a
crucial role in lymphoma development [83–85]. These molecu-
lar defects may prove useful targets in the future treatment and
management of DLBCL.
methodology
These clinical practice guidelines were developed in accordance
with the ESMO standard operating procedures for clinical prac-
tice guidelines development. The relevant literature has been
selected by the expert authors. A summary of recommendations
is shown in Table 5. Levels of evidence and grades of recom-
mendation have been applied using the system shown in
Table 6. Statements without grading were considered justified
standard clinical practice by the experts and the ESMO faculty.
This manuscript has been subjected to an anonymous peer
review process.
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